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Abstract 
Background: Molecular mediators influencing the transition from acute to persistent musculoskeletal pain follow‑
ing common stress exposures such as motor vehicle collision (MVC) remain poorly understood. In this exploratory, 
proof of concept study, we compared circulating microRNA (miRNA) expression profiles in the early aftermath of MVC 
among individuals who did and did not subsequently develop persistent pain. Blood RNA samples were obtained 
from African American individuals (n = 53) who presented to the emergency department after MVC and were dis‑
charged to home after evaluation. The presence or absence of severe pain in the axial region, the most common and 
morbid region in which post‑MVC pain occurs, was assessed 6 weeks following MVC via standardized questionnaire. 
miRNA expression was determined using miRNA‑sequencing; nonparametric analyses were used to compare miRNA 
expression levels among individuals with and without persistent pain.
Results: Thirty‑two mature miRNA were differentially expressed (p < 0.05) in those with and without severe axial 
pain at 6 weeks. miR‑135a‑5p, a regulator of the serotonin receptor that is known to be stress‑responsive, differed 
most significantly between groups (p = 3 × 10−4). This miRNA, and miR‑3613‑3p (p = 0.001) survived correction for 
multiple testing (FDR = 0.15) in this small sample. Interestingly, differentially expressed miRNA were enriched for X 
chromosome location. In secondary analyses, the eight X chromosome miRNA were (a) more significantly associated 
with axial pain in women than men, (b) expressed more highly in the peripheral blood of women than men, and (c) 
predicted in pathway analyses (DIANA miRPath v 2.0) to regulate neuronal and neuroendocrine pathways previously 
implicated in various pain pathologies.
Conclusions: These results show that circulating miRNA predict persistent severe axial pain after MVC and suggest 
that they may be involved in the pathogenesis of post‑traumatic musculoskeletal pain. However, further studies are 
needed to determine if these miRNA play a direct causal role.
Keywords: microRNA, Stress induced pain, Persistent axial pain, Motor vehicle collision, Sexual dimorphism, 
microRNA, Motor vehicle collision, African Americans, Musculoskeletal pain
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Background
MicroRNA (miRNA) are small non-coding RNA mol-
ecules that regulate gene expression by binding target 
mRNA. During the past decade, the study of miRNA has 
transformed understanding of the regulation of major 
biological pathways [1, 2] and advanced understanding of 
the pathogenesis of a number of common diseases (e.g. 
[3–5]). Substantial evidence suggests that miRNA may 
play a critical role in molecular pathways underpinning 
diverse pain conditions (e.g. [6–8]). Most of this evidence 
comes from animal studies; further human studies are 
needed which prospectively evaluate the potential role 
of miRNA in persistent pain development after potential 
triggering events.
One common potential triggering event for persistent 
pain is exposure to a motor vehicle collision (MVC). 
More than fifty million MVCs occur each year world-
wide [9], and more than 4 million individuals present to 
US emergency departments (ED) each year for care after 
MVC [10, 11]. Ninety percent of individuals presenting 
to US EDs for care after MVC are discharged home after 
evaluation with little or no identifiable tissue injury [12]. 
A substantial proportion of these individuals develop 
musculoskeletal pain, most commonly in the axial region 
(neck, shoulders, and/or back) [13].
The molecular mechanisms responsible for axial 
pain (AP) development after MVC remain poorly 
understood. This lack of understanding is a major bar-
rier to the development of more effective preventive 
interventions. If miRNA play an important role in the 
pathogenesis of post-MVC AP, then studies identifying 
differences in miRNA populations among those who do 
and do not subsequently develop these outcomes may 
advance understanding of post-MVC AP pathogenesis 
[14–16]. Such studies must be feasible and ethical, and 
should obtain miRNA samples from tissue relevant to 
disease pathogenesis and/or be representative of such 
tissue.
Several lines of evidence suggest that blood is not only 
a feasible source of miRNA for studies of post-MVC 
musculoskeletal pain pathogenesis, but also that blood 
miRNA studies may provide pathogenic insights [17–
19]. First, stress systems appear to be involved in the 
pathogenesis of persistent pain after MVC [20–23], and 
blood-borne stress and immune-related factors are an 
important component of the systemic stress response 
[24]. In addition, RNA expression patterns in blood, 
CNS, and endocrine tissues are strongly correlated [15, 
25, 26], and a number of previous studies have linked 
miRNA expression in blood with neurologic disease 
outcomes [27–30]. Finally, despite challenges related 
to tissue-specific gene expression, the study of blood 
miRNA expression has led to important new under-
standing of diverse diseases, including pain conditions 
[27, 31, 32].
In this prospective study, we compared ED blood 
miRNA profiles among individuals who presented to the 
ED for evaluation after MVC. We hypothesized that ED 
blood miRNA profiles would differ among those who did 
and did not have severe persistent AP 6 weeks later.
Results
Cohort
Characteristics of the study sample (n = 53) are shown 
in Table  1. Samples were drawn from a large prospec-
tive cohort study of African Americans (R01AR060852); 
all participants were African American (AA) and nearly 
six in ten were female. Most were less than 40 years old, 
had some college education, made less than 40 K annu-
ally, and were overweight (average BMI = 30). All indi-
viduals in this study presented to the ED within 6 h of 
MVC and most arrived within 1 h. Only individuals who 
were discharged from the ED who reported no lacera-
tions, avulsions, or major tissue injury were included. 
Additionally, participants all had a severity score of 1 
on the Abbreviated Injury Scale (AIS) [33], indicating 
minimal anatomical injury. Six weeks following MVC, 
severe AP was present in 27/53 participants. Among 
these 27 individuals who developed severe AP, 16 (59 %) 
were women.
miRNA sequencing quality assessment
An average of 9 million sequencing reads were obtained 
per participant from blood samples obtained in the ED 
Table 1 Study characteristics
Characteristic
Participants, n 53
Age, years, mean (SD) 37 (13)
Females, n (%) 31 (58)
Education, n (%)
 Some or all of high school 16 (30)
 Some college 25 (47)
 College 9 (17)
 Post‑college 2 (4)
Income, n (%)
 0–20 K 10 (19)
 20–40 K 18 (34)
 40–80 K 10 (19)
 >80 K 2 (4)
Body mass index, mean (SD) 30 (6)
Time to ED presentation in minutes, median 54
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in the early aftermath of MVC. More than 95 % of these 
miRNA aligned with miRNA in miRBase, indicating 
that the majority of the sequencing reads were mature 
miRNAs (vs. degradation products, linker–linker con-
taminants, etc.). Mature miRNA with an average of ≥300 
sequencing reads across all 53 samples (n = 376 miRNA) 
were included in analyses. Relative proportions of several 
miRNA typically found in peripheral blood were very sim-
ilar to those reported previously [15, 34] (data not shown).
Evaluation of ED miRNA expression levels among those 
who did and did not develop persistent AP 6 weeks 
following MVC
Thirty-two of 376 (9  %) miRNA detected in ED blood 
samples were differentially expressed at the p  <0.05 
level among those who did and did not report severe 
post-MVC AP at 6  weeks, with fold differences rang-
ing from −3.71 to 2.49 (Table 2, sequencing read counts 
used for determination of mean fold differences for each 
miRNA are included in Additional file 1: Table S1). Nine 
of these 32 differentially expressed miRNA have previ-
ously been associated with pain and/or stress system 
physiology in neurological tissue and/or blood (see ‘Ref ’ 
column, Table 2). Two of the 32 differentially expressed 
miRNA, miR-135a-5p (p = 3 × 10−4) and miR-3613-3p 
(p = 0.001), met our pre-hoc significance level threshold 
for multiple testing of 0.15, corresponding to a p value 
cut-off of <0.003 [35].
Validation of miRNA sequencing results using RT‑qPCR
Technical and qualitative validation of miRNA sequenc-
ing results was performed on a random subsample of 7 of 
the 32 differentially expressed miRNA using reverse tran-
scription quantitative-PCR (RT-qPCR) [36]. In each case, 
concordance between miRNA sequencing results and 
RT-qPCR results was observed for direction of differen-
tial expression (i.e., positive or negative expression dif-
ference, Fig. 1). Magnitude of direction of effect was also 
generally similar. The Spearman Correlation between the 
two methods was also calculated: r = 0.786 p = 0.036.
Differentially expressed miRNA were enriched for X 
chromosome location
Specific data regarding chromosomal origin and strand 
(sense or antisense) for the 32 differentially expressed 
miRNA is shown in Additional file  1: Table  S1. The 32 
miRNA predictive of severe post-MVC AP at 6  weeks 
were enriched for gene location on the X chromosome 
(Fig.  2) in comparison to all X chromosome miRNA 
identified in the sample (8/32 (25  %) vs. 28/376 (8  %), 
p = 0.038). This holds true despite the fact that approxi-
mately 8 % of the detected blood miRNA originate from 
the X chromosome.
X chromosome miRNA identified in this study are more 
highly associated with the development of persistent AP 
following MVC in women than men
Because X chromosome gene expression can be sex-
dependent [37], after we observed the X chromosome 
enrichment of differentially-expressed miRNA in our 
sample, we assessed for interactions between sex and the 
Table 2 microRNA in  whole blood circulating in  the early 
aftermath of  motor vehicle collision in  African Americans 
that  predict axial pain development 6  weeks after  MVC 
trauma
a Mean fold difference was calculated by dividing the average sequencing read 
counts for individuals developing axial pain by the average sequencing read 
counts for individuals who recover
b p values were calculated using the Mann–Whitney U test. Italicized miRNA 
remained significant after correcting for multiple testing (FDR = 0.15)
c Previous assoc = references describing a previously identified role for the 
miRNA in stress system biology (S), pain pathobiology (P), or neuropsychiatric 
disease (N)
microRNA Mean fold differencea p valueb Previous assocc
miR‑135a‑5p 2.49 3 × 10−4 S, N [47, 48]
miR‑3613‑3p 2.02 0.001
miR‑19b‑3p 1.67 0.004 S, P [49, 51]
miR‑502‑3p 1.75 0.004
miR‑500a‑3p 1.39 0.005
miR‑1296‑5p 1.99 0.006 S [50]
miR‑454‑5p 1.58 0.010
miR‑99a‑5p 1.48 0.010 P [71]
miR‑501‑5p −1.15 0.011
miR‑362‑5p 1.41 0.013
miR‑154‑5p 1.09 0.015
Let‑7a‑3p 1.48 0.020 S, P [50, 72]
miR‑185‑5p −3.45 0.021 P [52]
miR‑339‑5p 1.31 0.023
miR‑29c‑5p 1.67 0.023
miR‑4659b‑3p −2.19 0.023
miR‑15b‑5p −1.22 0.026
miR‑329‑3p 1.68 0.026
miR‑20b‑5p 1.35 0.029 S [73]
miR‑500b‑5p 1.38 0.029
Let‑7f‑2‑3p 1.43 0.029
miR‑7‑5p −2.12 0.033 P [53, 73]
miR‑378a 1.37 0.034
miR‑3130‑5p 1.91 0.034
miR‑532‑5p 1.31 0.036
miR‑345‑5p 1.62 0.037
miR‑16‑5p −2.70 0.043
miR‑18a‑3p 1.49 0.044
miR‑337‑3p −1.06 0.045
miR‑26b‑3p −3.71 0.046 P [54]
miR‑26a‑5p −2.52 0.048
miR‑151b 1.33 0.048
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effect on severe persistent AP of differentially expressed 
X chromosome miRNA. Even in the relatively small sam-
ples of men and women assessed, sex × miRNA interac-
tions were significant at the p <0.05 level for miR-362-5p 
and let-7f-2-3p, and were present at the trend level for 
miR-501-5p and miR-500b-5p (Table 3, Additional file 1: 
Table S1). Much greater differences in expression accord-
ing to pain outcome were observed in women (n =  31) 
vs. men (n  =  22) (Table  3). Seven of the 8 X chromo-
some miRNA were significantly associated with AP 
development in women, whereas none of the X chro-
mosome miRNA were associated with AP development 
in men (Table  3). Additionally, after discovering signifi-
cant sex  ×  miRNA interactions for the X-chromosome 
miRNA described above, we assessed for additional 
interactions between participant sex and miRNA associ-
ated with persistent AP. A significant sex × miRNA inter-
action was present for two additional miRNA, miR-1296 
(p  =  0.017) and Let-7a-3p (p  =  0.022) (see Additional 
file  1: Table  S1 for results of all sex  ×  miRNA interac-
tions). These two miRNA are significantly associated 
with persistent severe AP in women (p < 0.001 and 0.001) 
but not in men (Additional file 2: Table S2).
X chromosome miRNA identified in this study are 
expressed more highly in the blood in the early aftermath 
of MVC in women than men
Based on previous reports showing higher expression of 
some X chromosome genes in women than men (most 
notably in brain tissue [38] and possibly due to mecha-
nisms such as escape from X chromosome inactivation 
[39]), we assessed whether the X chromosome miRNA 
identified in this study are expressed at higher levels in 
women than men. All eight miRNA were expressed at 
higher levels in women than in men developing severe 
AP, although only one was statistically significant (miR-
502-3p, p = 0.017) (Table 4).
Evaluation of biologic pathways targeted by AP‑associated 
X chromosome miRNA
Using DIANA miRPath v 2.0 [40], we assessed for 
molecular pathways (KEGG pathways [41]) overrep-
resented in predicted targeting by these 8 X chromo-
some miRNA. The pathways with the highest number 
of gene transcripts targeted by the eight X chromo-
some miRNA in Table 2 (i.e. most statistically significant 
enrichment) out of  ~450 KEGG pathways that DIANA 
miRPath queries are shown in Table  5 (false discovery 
rates (FDRs) calculated via permutation testing [42]). 
These pathways include neuronal and neuroendocrine 
pathways such as the Long Term Potentiation path-
way (p = 1.67 × 10−9, FDR ≤ 0.08), the Axon Guidance 
pathway (p =  1.32 ×  10−7, FDR ≤  0.22), Neurotrophin 
signaling (p = 7.35 × 10−7, FDR ≤ 0.22) and the Dopa-
minergic synapse signaling pathway (p  =  1.56  ×  10−6, 
FDR  ≤  0.33). Substantial evidence supports an impor-
tant role for these pathways in mediating physiologic 
responses to stress and the pathogenesis of acute and 
-5
-4
-3
-2
-1
0
1
2
3
4
5
M
ea
n 
Fo
ld
 E
xp
re
ss
io
n 
Di
ffe
re
nc
e 
(A
P/
no
AP
) miRNA seq
RT-qPCR
Fig. 1 RT‑qPCR validation of microRNA that predict axial pain (AP) 
development following motor vehicle collision (MVC). Dark grey bars 
represent expression differences calculated using mean microRNA 
sequencing counts in individuals developing AP divided by mean 
microRNA sequencing counts in individuals recovering after MVC. 
Light grey bars represent expression differences in the same two 
groups using mean cycle thresholds generated via RT‑qPCR. Spear‑
man Correlation assessing correlation of the two methods: r = 0.786, 
p = 0.036
Fig. 2 microRNA that predict axial pain (AP) development are tran‑
scribed from 14 different chromosomes. The percentage of miRNAs 
(out of the 32 associated with AP, Table 2) that originate from each 
of the 14 chromosomes are represented by pieces of the pie chart 
based on shading (lightest shading = 3 % and darkest shading = 25 %, 
with intermediate percentages having intermediate shading colors, 
see legend). The names/number of each chromosome are labeled 
inside each piece of the pie
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persistent pain [43–45]. In addition to assessing X-linked 
miRNA targeted pathways, we also assessed which path-
ways might be enriched in targeting by all 32 miRNA 
associated with persistent AP development. This data is 
provided in Additional file 3: Table S3.
Discussion
Persistent pain is a common and poorly understood 
sequela of traumatic/stressful events such as MVC [46]. 
The results of this study show that even in the relatively 
small study sample, circulating blood miRNA in the first 
hours after stress exposure differed significantly among 
AAs who did and did not have severe persistent MVC-
related AP 6  weeks later. Study results also provide an 
example of the novel pathophysiologic insights that may 
be obtained, as enrichment of X chromosome miRNA 
Table 3 Association of Emergency Department expression levels of microRNA (miRNA) from the X chromosome with per-
sistent axial pain following motor vehicle collision in women vs. men and assessment of  interaction between sex of an 
individual and miRNA
a p values were calculated using the Mann–Whitney U test
b p values for the interaction term were calculated using a logistic regression model adjusted for age and site. P values meeting a significance threshold of p <0.05 are 
italicized
miRNA Women (n = 31) Men (n = 22) Interaction (sex × miRNA)
Fold difference P valuea Fold difference P valuea P valueb
miR‑502‑3p 2.17 0.001 1.17 0.562 0.400
miR‑500a‑3p 1.39 0.009 1.36 0.300 0.251
miR‑501‑5p −1.41 0.037 1.45 0.217 0.071
miR‑362‑5p 1.32 0.049 1.55 0.151 0.030
miR‑20b‑5p 1.47 0.012 1.12 0.847 0.878
miR‑500b‑5p 2.60 0.014 −1.36 0.606 0.054
Let‑7f‑2‑3p 6.9 0.001 −2.06 0.797 0.015
miR‑532‑5p 1.24 0.093 1.41 0.243 0.294
Table 4 Emergency Department expression level dif-
ferences of  microRNA (miRNA) from  the X chromosome 
in women vs. men developing persistent axial pain follow-
ing motor vehicle collision
a Expression difference is the mean sequencing read counts of the specified 
miRNA in women who have axial pain at 6 weeks divided by the mean 
sequencing read counts of men who have axial pain at 6 weeks
miRNA Expression differencea (women/men) P value
miR‑502‑3p 1.80 0.017
miR‑500a‑3p 1.43 0.112
miR‑501‑5p 1.38 0.209
miR‑362‑5p 1.08 0.773
miR‑20b‑5p 1.60 0.126
miR‑500b‑5p 1.37 0.417
Let‑7f‑2‑3p 1.78 0.252
miR‑532‑5p 1.15 0.563
Table 5 DIANA miRPath predicted KEGG pathways enriched in  targeting by  X chromosome miRNA differentially regu-
lated in the early aftermath of MVC trauma in AA individuals who develop AP following MVC vs. those who recover
* Denotes mRNA experimentally validated to interact with an miRNA from Table 2, as identified by TarBase v 7.0
KEGG pathway P value Example of predicted targets
Ubiquitin mediated proteolysis 2.15 × 10−10
Long‑term potentiation 1.67 × 10−9 PRKCA*, CAMK4, GRIA1, PPP3CC, KRAS, CALM2*, GRIA2, PPP3CA, GRM1, RPS6KA3*, EP300*, GNAQ*
Axon guidance 1.32 × 10−7 GSK3B*, ABLIM3, SEMA5A, EPHA5, ROCK2*, PAK7, ROBO2, SEMA3C*, SRGAP1*, PPP3CC, KRAS, EPHA7, PPP3CA, 
PTK2*, RASA1*, NFAT5*, EPHB4*, UNC5C, CFL2*, SEMA3D, SEMA3A*, PLXNC1*, EPHA4*, SEMA3E, UNC5D
ErbB signaling 7.04 × 10−7
Neurotrophin signaling 7.35 × 10−7 GSK3B, NTRK2*, CAMK4, CRK, SORT1*, NTRK3*, FRS2*, MAP3K1*, KRAS, CALM2*, JUN, MAPK8, SOS1*, 
RPS6KA3*, GAB1, AKT3*, CAMK2B, FOXO3, MAP2K1, PRDM4, RAP1B, MAP3K5
Insulin signaling 8.72 × 10−7
Dopaminergic synapse 1.56 × 10−6 FOS, GSK3B*, PRKCA*, PPP2R5E, PPP2R3A, PPP2R2C, CREB5, DRD1, GRIA1, PPP3CC, CALM2*, GRIA2, PPP3CA, 
MAPK8, PPP2R2A, SCN1A, PPP2R3C, GNAQ, PPP2CB, AKT3*, CAMK2B, PPP1CB, GRIA3
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among differentially expressed miRNA, and sex differ-
ences in the effect of these miRNA, suggest potential 
mechanisms contributing to sex differences in vulner-
ability to persistent post-MVC pain. Supporting the role 
of these differentially expressed miRNA in persistent 
pain pathogenesis, these miRNA included a number of 
miRNA previously associated with the stress response 
and/or pain processing. However, further studies are 
needed to determine whether these miRNA play a causal 
role in the pathogenesis of pain post-MVC. Of note, 
study findings also support the legitimacy of persistent 
post-MVC musculoskeletal pain as a “real” disease out-
come. This is important, as patients with post-MVC pain 
outcomes are highly stigmatized [47]. In addition, study 
findings also contribute to a growing literature indicating 
that stress-mediated changes in neurosensory processing 
play an important role in the pathogenesis of post-MVC 
outcomes.
We do not know whether miRNA predicting severe 
AP in the present study play a causal role in the develop-
ment of these outcomes, or are markers for other cellular 
processes directly involved. If these miRNA play a causal 
role, mechanisms by which miRNA detected in blood 
may directly influence AP outcomes include: (1) miRNA 
expressed outside the central nervous system (CNS) and 
detected in the blood may cross the blood brain bar-
rier [48, 49] to influence CNS processes, (2) miRNA 
expressed in the CNS may alter CNS transcription and 
also be released into the periphery (e.g., as part of a cellu-
lar/systemic communication system [50, 51]), (3) miRNA 
expressed outside the CNS may influence extra-CNS 
processes involved in the pathogenesis of post-traumatic 
pain [52, 53] (animal model data suggest that systemic, 
extra-CNS processes may play an important role in the 
pathogenesis of stress-induced pain [54]). Future studies 
are needed to better understand the identified associa-
tions between miRNA circulating in the immediate after-
math of trauma and the development of persistent pain 
states. Such studies may provide new insights into the 
biology of chronic pain development.
A potential causal role of the miRNA identified in the 
present study in the pathogenesis of severe post-MVC 
axial pain is supported by the known role of several of 
these miRNA in pain and/or stress-related processes. For 
example, miR-135a-5p binds the mineralcorticoid recep-
tor (NR3C2) [55], the serotonin transporter (SLC6A4) 
[56], and the serotonin receptor-1a (HTR1A) [56] tran-
scripts, all of which can affect pain processing (e.g. [57–
59]), and miR-135a-5p has been shown to be expressed in 
pain-relevant tissues including the amygdala [60], 5-HT 
neurons [56], spinal cord [61], and pre-frontal cortex 
[62]. miR-19b-3p has been shown to be stress responsive 
in both the amygdala [63] and blood leukocytes [64], and 
can regulate the adrenergic receptor β-1 (ADRB1) [63]. 
Other miRNA, such as miR-3613-3p, have not been stud-
ied extensively; target prediction algorithms (e.g., Tar-
getScan v7.0) predict that miR-3613-3p modulates the 
expression of pain-associated genes including GABRB3, 
GRIN3A, TRPV1, NPY1R, and SCN9A. Further examples 
of miRNA identified in this study that have prior asso-
ciations with pain include miR-185-5p, miR-7-5p, and 
miR-26b-3p [61, 62, 65]. Equally important, many of the 
miRNA identified in this study are not currently known 
to be associated with stress or pain-related outcomes, 
suggesting that investigations such as the present study 
have the potential to lead to the identification of novel 
miRNA mediators.
An unexpected finding in the present study was that 
differentially expressed miRNA were enriched for 
miRNA located on the X chromosome. This finding holds 
true even accounting for the relatively high abundance 
of X chromosome miRNA expressed in the blood (8 %) 
compared to miRNA from other chromosomes. These 
X chromosomal miRNA were consistently expressed at 
higher levels in women than in men and appeared to con-
tribute to persistent severe AP in women but not in men. 
These X chromosome miRNA were predicted to target 
pain-relevant transcripts from KEGG pathways known to 
be associated with various pain phenotypes, such as long 
term potentiation, neurotrophin signaling, and dopa-
minergic signaling [43–45]. Pathophysiologic mecha-
nisms by which these miRNA may contribute to severe 
post-MVC AP in women but not in men are currently 
unknown. Six of the eight X chromosome miRNA iden-
tified to be associated with persistent severe AP in this 
study are transcribed as part of the miR-532-502 cluster 
of miRNA (a cluster which includes the expression of 
miR-532, -188, -500, -362, -501, -500b, -660, and -502). 
Upon examination of DNase hypersensitivity regions 
upstream of this cluster and upstream of miR-20b-5p and 
let-7f-2-3p, we did not find any obvious binding regions 
for sex hormone responsive transcription factors (TFs). 
However, let-7f-2-3p has been shown experimentally to 
be induced by estradiol and is in a dosage sensitive region 
of the X chromosome [66]. In addition to sex hormone 
responsive TFs, another mechanism that may contrib-
ute to the observed sex differences in miRNA effect is X 
chromosome inactivation. This phenomenon is believed 
to influence the transcription of ~15 % of all X chromo-
some genes [67, 68], and the results of at least two other 
studies suggest that miRNA genes can escape X chro-
mosome inactivation. One study found that X chromo-
some miRNA genes are over-expressed in the T cells of 
women with lupus [69], and another study found sex-
biased miRNA expression in the neonatal brain [70]. Fur-
ther studies are needed to assess for associations between 
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X chromosome miRNA expression and pain outcomes 
in men and women experiencing MVC, and to evaluate 
potential physiologic mechanisms by which sex differ-
ences in the expression of these miRNA may occur.
Some limitations should be considered when inter-
preting the results of this study. First, the sample size of 
this initial proof-of-concept study was relatively small. 
Future studies with much larger samples and greater 
power are needed. These studies should also adjust 
more stringently for multiple comparisons to reduce the 
probability of Type I error. Second, we did not adjust 
for potential confounders such as participant age, sex, 
or BMI in our primary analyses. However, adjusting 
for these factors in exploratory analyses did not dimin-
ish our effect size estimates. Third, we were not able to 
adjust for the potential confounding influence of medi-
cations administered in the ED and miRNA expression. 
We were able to evaluate chronic medication use in 
our cohort: no individuals in the study were taking opi-
oids (due to exclusion criteria), 4 % of individuals were 
taking acetaminophen, and 13  % were taking NSAID. 
Adjusting for pre-MVC acetaminophen or NSAID use 
had negligible effect on effect size estimates for the 
association between miR-135a-5p and miR-3613-3p and 
severe AP development. Similarly, we were also unable 
to adjust for any potential confounding effect due to 
pre-MVC chronic illnesses, as comprehensive past med-
ical history data on study participants was not available. 
Data from the emergency department record, for which 
past medical history data is often incomplete, indicated 
that the most prevalent chronic illnesses in the cohort 
were hypertension (25 %) and asthma (13 %). Hyperten-
sion was not associated with the development of severe 
AP (p = 0.757), and adjusting for hypertension did not 
weaken the association between miR-135a-5p and miR-
3613-3p and severe AP development. Similar results 
were obtained when assessing the potential effect of 
asthma. Fourth, miRNA expression differences between 
those who did and did not develop severe AP were eval-
uated in the ED, in the early aftermath of MVC, and 
we do not know how the expression of these miRNA 
changed over time. However, we found that even in 
the very early aftermath of MVC, miRNA expression 
differed in those who did and did not subsequently 
develop persistent pain. Fifth, our study population was 
limited to African Americans, an understudied group 
that has been shown to experience an increased bur-
den of adverse pain outcomes after trauma [71–74]. The 
generalizability of our findings to other ethnic groups is 
unknown. Sixth, larger sex specific strata are needed to 
fully understand miRNA expression differences associ-
ated with persistent severe AP development in women 
vs. men. Finally, pathway and gene target identification 
analyses were based on predicted binding rather than 
actual binding in biologic assays. However, predicted 
binding has been shown to have high concordance with 
actual binding, and predicted binding has the advantage 
of providing an unbiased assessment across the entire 
genome [75].
Conclusion
The results of this study show that two miRNA, miR-
135a-5p and miR-3613-3p, predict persistent AP devel-
opment after MVC. In addition, study results suggest 
that X chromosome miRNA contribute to persistent 
pain development after MVC stress exposure in women, 
and that such miRNA may contribute to sex differences 
in vulnerability to persistent pain after MVC. More 
broadly, the results of this study support the hypothesis 
that analyses of miRNA collected from blood in the early 
aftermath of trauma/stress exposure might provide new 
insights into mechanisms of persistent pain development. 
Further studies are needed in larger samples of individu-
als experiencing MVC, both to validate current find-
ings and to provide greater power to discover associated 
miRNA. Additionally, further experiments are needed to 
show whether the miRNA identified in this study play a 
causal role in persistent pain pathogenesis. The results of 
such studies may provide an important new window into 
these yet enigmatic processes.
Methods
Study design and setting
This prospective longitudinal study enrolled African 
American individuals who presented within 24 h of MVC 
to one of eight EDs in three states (Michigan, Pennsylva-
nia, and Florida) between July 2012 and July 2013. The 
study only enrolled African Americans because of the 
pressing need for pain studies that focus on such under-
studied, high risk groups [74, 76–79]. The study was 
approved by the institutional review boards of all par-
ticipating hospitals. Each participant provided written 
informed consent before enrollment.
Participant eligibility criteria
Individuals  ≥18 and  ≤65  years of age presenting to 
the ED within 24  h of MVC who did not have frac-
ture or other injury requiring hospital admission were 
screened for eligibility. Patients who were not alert and 
oriented were excluded, as were patients who did not 
self-identify as African American, pregnant patients, 
prisoners, patients unable to read and understand Eng-
lish, or patients taking opioids above a total daily dose of 
30 mg of oral morphine or equivalent.
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Study procedures
Eligible and consenting participants provided a blood 
sample in the ED and completed an ED interview evalu-
ation. Interview evaluations were performed by research 
assistants at the time of the ED visit using a web-based 
survey with explicit definitions of variables. Before 
enrolling patients in the ED, each research assistant com-
pleted a study training module followed by an interview 
with a standardized mock ED patient. Comparison of 
mock ED patient data across research assistants dem-
onstrated an error rate of 0.57  %. Injury characteristics 
and medications administered in the ED were obtained 
by data extraction from the ED medical record. Six weeks 
after the MVC, participants completed a follow-up inter-
view by telephone, online, or via mail. Participants were 
compensated $75 for completing the ED protocol and 
$50 for completing the 6-week interview.
Participant demographics
Participant demographic characteristics (including age, 
gender, income, height, weight, and educational attain-
ment) were obtained from the ED medical record and 
from participant self-report.
Pain assessments and outcome definitions
Severity of pain in each body region during the month 
prior to MVC was assessed at the time of ED evaluation 
using a 0–-10 Numeric Rating Scale (NRS) score [80]. 
Severity of pain due to MVC in each body region was 
assessed at the 6 week time point using this same method 
together with an assessment of the MVC-relatedness of 
the pain. Individuals reporting a pain severity score ≥7 in 
at least one axial body region (neck, upper back, lower 
back, left shoulder, right shoulder) were defined as hav-
ing severe AP [81, 82]. Individuals reporting severe AP 
during the month prior to the MVC were excluded from 
analyses.
RNA collection and isolation
Research assistants collected blood samples in the ED at 
the time of enrollment using PAXgene RNA tubes. Total 
RNA (including miRNA) was isolated using the PAX-
gene blood miRNA kit (Qiagen, Valencia, CA, USA) and 
stored at −80 °C until use. RNA concentration and purity 
were measured using a NanoDrop 1000 (Nanodrop Tech-
nologies, Wilmington, DE).
Library preparation and miRNA sequencing
Template libraries for miRNA Sequencing were produced 
from 1.0 ug total RNA using an adaptation of published 
protocols [83]. Briefly, total RNA was sequentially ligated 
to a 3′ linker using T4 RNA ligase 2, polyacrylamide gel 
extracted to remove excess 3′ linker, then ligated via T4 
RNA ligase 1 to an oligonucleotide adapter (sequences 
shown in Additional file  4: Table  S4). The 5′ adapter 
contained a two nucleotide barcode for multiplexing 
libraries. RNA products were reverse transcribed and 
amplified by PCR. In order to purify the miRNA popu-
lation, gel isolation was used to obtain template libraries 
with 15–40 nucleotide inserts. Twelve barcoded libraries 
were combined per lane and sequenced on a HiSeq 2000 
(Illumina, San Diego, CA, USA).
Bioinformatics analysis and data normalization
Raw sequence reads were processed using a custom 
bioinformatics pipeline. Reads were de-multiplexed 
and barcode and adapter sequences removed. Mature 
miRNA sequences were obtained from miRbase v18.0 
and genomic extensions were added before aligning 
with sequencing reads. Total read counts were generated 
including isomir and non-templated nucleotide addi-
tion. Sequencing reads were normalized using quantile 
normalization. In order to avoid individual samples with 
lowly abundant or no miRNA expression, miRNA species 
with less than 300 reads across samples were dropped 
from analyses (adapted as described previously [28]).
RT‑qPCR validation
The miRNA RT-qPCR method used is based on the stem-
loop method described by Chen et  al. [36]. Stem-loop 
RT primers and TaqMan probes for each miRNA were 
obtained from Life Technologies (Carlsbad, CA, USA). 
MiRNA expression of each miRNA was normalized to 
RNU48 levels before determination of expression differ-
ences. RT-qPCR validation was performed on a subset of 
the significant miRNA identified by miRNA sequencing 
(due to limited quantities of participant RNA).
Statistical analysis
Differences in ED miRNA expression between those who 
did and did not subsequently develop AP were quantified 
by dividing the mean expression levels in the two groups. 
Because miRNA distributions were non-normal [Kol-
mogorov–Smirnov (K-S) test], expression levels of indi-
vidual miRNA among individuals with and without AP, 
including for women and men subgroup analyses, were 
compared using the Wilcoxon-Mann–Whitney (WMW) 
test. Logistic regression models were used to test for sex-
miRNA interactions while adjusting for age and ED study 
site. To account for multiple testing, we used the meth-
ods of False Discovery Rate (FDR) determination defined 
by Benjamini and Hochberg [35]. For this initial proof-of-
concept discovery cohort, p value thresholds were set at 
p <0.05 and an FDR cut-off corresponding to 0.15. Statis-
tical analyses were carried out using SPSS software ver-
sion 21.0 or SAS University Edition.
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Identification of biologic pathways targeted 
by differentially expressed miRNA
A web-based computational tool, DIANA miRPath v2.0, 
was used to identify molecular pathways overrepre-
sented in predicted targeting by differentially expressed 
miRNA originating from the X chromosome [79]. Path-
way enrichment was also performed for the full set of 
32 miRNA identified in Table  2. DIANA miRPath uses 
its predictive binding algorithm, DIANA-microT-CDS, 
to define a list of potential targets for each miRNA, then 
assigns a Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway [41] rank and significance level based 
on the relative number of targets in that pathway [79]. 
DIANA miRPath results have been validated and its pre-
dictive binding algorithm has been shown to have high 
concordance with actual miRNA binding (e.g. [88, 90]). 
MiRNA that have been experimentally validated to bind 
to the predicted mRNA were identified using TarBase 
v2.0 [84]. The false discovery rates of the most highly 
ranked pathways were evaluated using permutation test-
ing [42].
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